Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Clinical Trial of Pembrolizumab as Monotherapy and in Combination With Cisplatin+5-Fluorouracil in Subjects With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Next Previous
Trial Profile

A Phase II Clinical Trial of Pembrolizumab as Monotherapy and in Combination With Cisplatin+5-Fluorouracil in Subjects With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 08 Mar 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary) ; Capecitabine; Cisplatin; Fluorouracil
  • Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms KEYNOTE-059
  • Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.

Most Recent Events

  • 11 Sep 2023 Result of pooled analysis from KEYNOTE-001,KEYNOTE-059, KEYNOTE-048, KEYNOTE-427, KEYNOTE-052, KEYNOTE-361 assessing Tumor dynamics in patients with solid tumors treated with pembrolizumab beyond disease progression published in the Cancer Cell
  • 01 Oct 2022 Results (n=1194) of retrospective analysis of two studies(KEYNOTE-001 and KEYNOTE-059) assessing Lesion-to-lesion heterogeneity in response to pembrolizumab therapy presented at the CRI-ENCI-AACR 6th Annual International Cancer, Immunotherapy Conference
  • 21 Sep 2021 Results assessing genomic landscape of late-stage gastric cancer from these two studies (KEYNOTE-059 and KEYNOTE-061) presented at the 46th European Society for Medical Oncology Congress

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top